Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $48.00 on Abbott Laboratories (NYSE:ABT) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $2.20 for the next fiscal and $N/A for underway quarter.
Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of Abbott Laboratories (NYSE:ABT) stands at 29.68.
Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For Abbott Laboratories Common Stoc, the PEG ratio for coming 3-5 years is 2.19.
The technical analysis highlights that Abbott Laboratories Common Stoc current is trading $2.26 points away or +5.29% from its 50-day moving average of $42.70. Further it is trading $4.56 or +11.29% away its 200-day moving average of $40.40.
The 52-week high of Abbott Laboratories (NYSE:ABT) was $50.60 while lowest point recorded in 52-week was $36.00. It implies if stock price makes a movement of over $-5.64, it will record a new 52-week high. In the case of +24.89% drop, it will touch a new 52-week low.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...